You are here
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).
Gastrointestinal (Colorectal) Cancer
Session Type and Session Title:
Oral Abstract Session, Gastrointestinal (Colorectal) Cancer
J Clin Oncol 30, 2012 (suppl; abstr 3502)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Regorafenib (REG) is an oral multi-kinase inhibitor. The CORRECT trial was conducted to evaluate REG in patients (pts) with mCRC who had progressed after all approved standard therapies. Methods: Enrollment criteria included documented mCRC and progression during or ≤3 months after last standard therapy. Pts were randomized 2:1 to receive best supportive care plus either REG (160 mg od po, 3 wks on/1 wk off) or placebo (PL). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate, disease control rate, safety and quality of life (QoL). Efficacy analyses across prespecified subgroups were evaluated using univariate Cox regression. Results: 760 pts were randomized (REG: 505; PL: 255). The OS primary endpoint was met at a preplanned interim analysis. OS and PFS were significantly improved in REG arm compared to PL arm: hazard ratio (HR) for OS 0.77 (95% CI 0.64-0.94, 1-sided p=0.0052), median OS 6.4 vs 5.0 mos; HR for PFS 0.49 (95% CI 0.42-0.58, 1-sided p<0.000001), median PFS 1.9 vs 1.7 mos. Comparable OS and PFS benefits were observed in exploratory subgroup analyses by region, age, time from diagnosis of mCRC to randomization, prior lines of treatment, and KRAS status (shown in table). The most common grade 3+ AEs related to REG were hand-foot skin reaction (16.6%), fatigue (9.6%), hypertension (7.2%), diarrhea (7.2%) and rash/desquamation (5.8%). QoL data will be presented. Conclusions: REG demonstrated statistically significant improvement in OS and PFS over PL, as well as comparable efficacy benefits across pt subgroups analyzed.
|HR||95% CI||HR||95% CI|
|North America, Western EU,
Israel and Australia
|< 65 yrs||475||0.72||0.56-0.91||0.42||0.34-0.51|
|≥ 65 yrs||285||0.86||0.61-1.19||0.65||0.50-0.86|
|Time from Dx of mCRC to randomization|
|< 18 mo||140||0.82||0.53-1.25||0.58||0.41-0.84|
|≥ 18 mo||620||0.76||0.61-0.95||0.48||0.40-0.58|
|No. of prior treatment lines on or after metastatic disease|
* 24 pts from other regions not shown. ^ Historical record.
Abstracts by Eric Van Cutsem:
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.Meeting: 2016 Gastrointestinal Cancers Symposium | Abstract No: 335
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).Meeting: 2016 Gastrointestinal Cancers Symposium | Abstract No: TPS178
A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).Meeting: 2016 Gastrointestinal Cancers Symposium | Abstract No: 05
Presentations by Eric Van Cutsem:
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial.Meeting: 2010 Gastrointestinal Cancers Symposium Abstract No: 281Session: Oral Abstract Session: Cancers of the Colon and Rectum (Oral Abstract Session)